Search

Your search keyword '"Silk, Ann W."' showing total 281 results

Search Constraints

Start Over You searched for: Author "Silk, Ann W." Remove constraint Author: "Silk, Ann W."
281 results on '"Silk, Ann W."'

Search Results

51. A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.

52. Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC).

53. A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).

55. BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma

62. Abstract 2846: Stereotypic patterns and genomic correlates of organotropism in metastatic melanoma

63. Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study

66. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer

68. Cyclooxygenase inhibitor use during checkpoint immunotherapy and effect on time to progression and overall survival for metastatic melanoma and non-small cell lung cancer patients.

71. A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab.

72. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

74. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

82. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

83. Clinical characterization of colitis arising from anti-PD-1 based therapy

84. Abstract 2765: Combination ONC201 and radiation therapy in the treatment of breast cancer

85. Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

86. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

88. A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).

89. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

90. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer

92. Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 ( C V A 21) and systemicp emb r olizumab ina dvanced melanoma patients: Interim results of the CAPRA clinical trial

93. Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC).

94. Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.

95. Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients.

98. Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.

99. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Catalog

Books, media, physical & digital resources